Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Noninvasive assessment of respiratory muscle strength and activity in Myotonic dystrophy.

Evangelista MA, Dias FAL, Dourado Júnior MET, do Nascimento GC, Sarmento A, Gualdi LP, Aliverti A, Resqueti V, Fregonezi GAF.

PLoS One. 2017 Jun 8;12(6):e0177318. doi: 10.1371/journal.pone.0177318. eCollection 2017.

2.

Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy.

Gadalla SM, Hilbert JE, Martens WB, Givens S, Moxley RT 3rd, Greene MH.

Eur J Neurol. 2017 May;24(5):713-718. doi: 10.1111/ene.13276. Epub 2017 Mar 20.

PMID:
28317292
3.

Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice.

Carrell ST, Carrell EM, Auerbach D, Pandey SK, Bennett CF, Dirksen RT, Thornton CA.

Hum Mol Genet. 2016 Oct 1;25(19):4328-4338. doi: 10.1093/hmg/ddw266. Epub 2016 Aug 13.

PMID:
27522499
4.

A tell tale handshake.

Wander P, Iluyomade A, Sanmartin P, Gupta A, O'Sullivan M.

Respir Med Case Rep. 2016 May 3;18:76-7. doi: 10.1016/j.rmcr.2016.04.010. eCollection 2016.

5.

Overweight Is an Independent Risk Factor for Reduced Lung Volumes in Myotonic Dystrophy Type 1.

Seijger CG, Drost G, Posma JM, van Engelen BG, Heijdra YF.

PLoS One. 2016 Mar 25;11(3):e0152344. doi: 10.1371/journal.pone.0152344. eCollection 2016.

6.

Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.

Pandey SK, Wheeler TM, Justice SL, Kim A, Younis HS, Gattis D, Jauvin D, Puymirat J, Swayze EE, Freier SM, Bennett CF, Thornton CA, MacLeod AR.

J Pharmacol Exp Ther. 2015 Nov;355(2):329-40. doi: 10.1124/jpet.115.226969. Epub 2015 Sep 1.

7.

[Cardiac involvement in Steinert myotonic dystrophy: Moroccan experience, about 18 cases].

Saghi G, Bouhouch R, Salaheddine L, Birouk N, Nadifi S, Fellat I, Cherti M.

Pan Afr Med J. 2015 Feb 16;20:131. doi: 10.11604/pamj.2015.20.131.2751. eCollection 2015. French. No abstract available.

8.

Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress.

Koutsoulidou A, Kyriakides TC, Papadimas GK, Christou Y, Kararizou E, Papanicolaou EZ, Phylactou LA.

PLoS One. 2015 Apr 27;10(4):e0125341. doi: 10.1371/journal.pone.0125341. eCollection 2015.

9.

Cardiac involvement in myotonic dystrophy.

Khalighi K, Kodali A, Thapamagar SB, Walker SR.

J Community Hosp Intern Med Perspect. 2015 Feb 3;5(1):25319. doi: 10.3402/jchimp.v5.25319. eCollection 2015.

10.

Modifications to toxic CUG RNAs induce structural stability, rescue mis-splicing in a myotonic dystrophy cell model and reduce toxicity in a myotonic dystrophy zebrafish model.

deLorimier E, Coonrod LA, Copperman J, Taber A, Reister EE, Sharma K, Todd PK, Guenza MG, Berglund JA.

Nucleic Acids Res. 2014 Nov 10;42(20):12768-78. doi: 10.1093/nar/gku941. Epub 2014 Oct 10.

11.

Myotonic dystrophy.

Thornton CA.

Neurol Clin. 2014 Aug;32(3):705-19, viii. doi: 10.1016/j.ncl.2014.04.011. Epub 2014 Jun 6. Review.

12.

Hypogonadism and erectile dysfunction in myotonic dystrophy type 1.

Peric S, Nisic T, Milicev M, Basta I, Marjanovic I, Peric M, Lavrnic D, Rakocevic Stojanovic V.

Acta Myol. 2013 Oct;32(2):106-9.

13.

Orthopaedic Disorders in Myotonic Dystrophy Type 1: descriptive clinical study of 21 patients.

Schilling L, Forst R, Forst J, Fujak A.

BMC Musculoskelet Disord. 2013 Dec 1;14:338. doi: 10.1186/1471-2474-14-338.

14.

Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis.

Gadalla SM, Pfeiffer RM, Kristinsson SY, Björkholm M, Hilbert JE, Moxley RT 3rd, Landgren O, Greene MH.

PLoS One. 2013 Nov 13;8(11):e79851. doi: 10.1371/journal.pone.0079851. eCollection 2013.

15.

Molecular genetics and genetic testing in myotonic dystrophy type 1.

Savić Pavićević D, Miladinović J, Brkušanin M, Šviković S, Djurica S, Brajušković G, Romac S.

Biomed Res Int. 2013;2013:391821. doi: 10.1155/2013/391821. Epub 2013 Mar 18. Review.

16.

Functional and histopathological identification of the respiratory failure in a DMSXL transgenic mouse model of myotonic dystrophy.

Panaite PA, Kuntzer T, Gourdon G, Lobrinus JA, Barakat-Walter I.

Dis Model Mech. 2013 May;6(3):622-31. doi: 10.1242/dmm.010512. Epub 2012 Nov 23.

17.

Structural and functional cardiac changes in myotonic dystrophy type 1: a cardiovascular magnetic resonance study.

Hermans MC, Faber CG, Bekkers SC, de Die-Smulders CE, Gerrits MM, Merkies IS, Snoep G, Pinto YM, Schalla S.

J Cardiovasc Magn Reson. 2012 Jul 24;14:48. doi: 10.1186/1532-429X-14-48.

18.

Muscular dystrophies at different ages: metabolic and endocrine alterations.

Cruz Guzmán Odel R, Chávez García AL, Rodríguez-Cruz M.

Int J Endocrinol. 2012;2012:485376. doi: 10.1155/2012/485376. Epub 2012 Jun 3.

19.

Modifying the Medical Research Council grading system through Rasch analyses.

Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, Cornblath DR, van der Kooi AJ, Cats EA, van den Berg LH, Notermans NC, van der Pol WL, Hermans MC, van der Beek NA, Gorson KC, Eurelings M, Engelsman J, Boot H, Meijer RJ, Lauria G, Tennant A, Merkies IS; PeriNomS Study Group.

Brain. 2012 May;135(Pt 5):1639-49. doi: 10.1093/brain/awr318. Epub 2011 Dec 20.

20.

Cancer risk among patients with myotonic muscular dystrophy.

Gadalla SM, Lund M, Pfeiffer RM, Gørtz S, Mueller CM, Moxley RT 3rd, Kristinsson SY, Björkholm M, Shebl FM, Hilbert JE, Landgren O, Wohlfahrt J, Melbye M, Greene MH.

JAMA. 2011 Dec 14;306(22):2480-6. doi: 10.1001/jama.2011.1796.

Supplemental Content

Support Center